This study aims to assess the neutralizing antibody levels and prevalence risk of Japanese encephalitis among residents in low-endemic areas, as well as to evaluate the immunogenicity, safety, and immune persistence of the inactivated Japanese encephalitis vaccine across different age groups in healthy populations. The study uses an open-label, single-arm trial design with a sample size of 250 participants. Primary endpoints include pre- and post-vaccination serum neutralizing antibody levels, seroconversion rates, and incidence of adverse events.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessment of JE neutralizing antibody levels in low-prevalence areas to evaluate the risk of JE transmission.
Timeframe: Prior to administration of the first vaccine dose.
Seroconversion rate and average neutralizing antibody levels against JE on the 28th day after vaccination.
Timeframe: On the 28th day after vaccination.